Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None20242023202220212020 September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock September 21, 2020 Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock September 8, 2020 Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications September 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 3, 2020 Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview July 28, 2020 Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations July 24, 2020 Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors July 2, 2020 CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 26, 2020 Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease May 13, 2020 Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview May 11, 2020 ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Next page › Last page » Displaying 61 - 72 of 76 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None20242023202220212020 September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock September 21, 2020 Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock September 8, 2020 Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications September 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 3, 2020 Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview July 28, 2020 Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations July 24, 2020 Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors July 2, 2020 CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 26, 2020 Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease May 13, 2020 Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview May 11, 2020 ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Next page › Last page » Displaying 61 - 72 of 76
September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
September 21, 2020 Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
September 8, 2020 Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
September 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2020 Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview
July 28, 2020 Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
July 2, 2020 CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 26, 2020 Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
May 13, 2020 Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview
